An alphaScreen TM-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction

Journal of Biomolecular Screening

Volumn 14, Issue 3, 2009, Pages 273-381

  Yi, Fang ^a   Zhu, Pingjun ^b   Southall, Noel ^b   Inglese, James ^b   Austin, Christopher P ^b   Zheng, Wei ^b   Regan, Lynne ^a  

^a YALE UNIVERSITY   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

AlphaScreen ., ; Heat shock protein 90 (Hsp90); High throughput screening (HTS); Hsp organizing protein (HOP); Tetratricopeptide repeat (TPR)

Indexed keywords

HEAT SHOCK PROTEIN 90; PROTEIN INHIBITOR; BIOTIN; CHAPERONE;

ANALYTICAL EQUIPMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; GENE LIBRARY; PRIORITY JOURNAL; PROTEIN FUNCTION; SCREENING; BIOLOGICAL MODEL; BIOTINYLATION; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; PROTEIN BINDING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME; TUMOR CELL LINE;

BIOTIN; BIOTINYLATION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 63849342150     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108330114     Document Type: Article

References (22)

1. Neckers L.: Heat shock protein 90: the cancer chaperone. J Biosci 2007 ; 32: 517-530.
2. Powers MP, Workman P.: Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007 ; 581: 3758-3769.
3. Chiosis G., Timaul MN, Lucas B., Munster PN, Zheng, FF, Sepp-Lorenzino L., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001 ; 8: 289-299.
4. Hardcastle A., Tomlin P., Norris C., Richards J., Cordwell M., Boxall K., et al. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol Cancer Ther 2001 ; 6: 1112-1122.
5. Goetz MP, Toft D., Reid J., Ames M., Stensgard B., Safgren S., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005 ; 23: 1076-1087.
6. Solit DB, Ivy SP, Kopil C., Sikorski R., Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007 ; 13: 1775-1782.
7. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S., Friedland D., Agarwala SS, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007 ; 13: 1769-1774.
8. Caplan AJ: What is a cochaperone? Cell Stress Chaperones 2003 ; 8: 105-107.
9. Pearl LH, Prodromou C., Workman P.: The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008 ; 3: 439-453.
10. Chen S., Smith DF: Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem 1998 ; 273: 35194-35200.
11. Scheufler C., Brinker A., Bourenkov G., Bartunik H., Hartl FU, Moarefi I.: Structure of TPR domain-peptide complexes: critical elements of the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000 ; 101: 199-210.
12. Brinker A., Scheufler C., von der Mulbe F., Fleckenstein B., Herrmann C., Jung G., et al. Ligand discrimination by TPR domains: relevance and selectivity of EEVD-recognition in Hsp90-HOP-Hsp90 complexes. J Biol Chem 2002 ; 277: 19265-19275.
13. Chen MS, Silverstein AM, Pratt WB, Chinkers M.: The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem 1996 ; 271: 32315-32320.
14. Cortajarena AL, Yi F., Regan L.: Designed TPR modules as novel anticancer agents. ACS Chem Biol 2008 ; 3: 161-166.
15. Ullman EF, Kirakossian H., Singh S., Wu ZP, Irvin BR, Pease PS, et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994 ; 91: 5426-5430.
16. Warner G., Illy C., Pedro L., Roby P., Bosse R.: AlphaScreen kinase HTS platforms. Curr Med Chem 2004 ; 11: 721-730.
17. Inglese J., Auld DS, Jadhav A., Johnson RL, Simeonov A., Yasgar A., et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006 ; 103: 11473-11478.
18. Feng BY, Shoichet BK: A detergent-based assay for the detection of promiscuous inhibitors. Nat Protocols 2002 ; 1: 550-553.
19. McGovern SL, Helfand BT, Feng B., Shoichet BK: A specific mechanism of nonspecific inhibition. J Med Chem 2003 ; 46: 4265-4272.
20. Yi F., Regan L.: A novel class of Hsp90 inhibitors. ACS Chem Biol. In press.
21. Roe SM, Ali MM, Meyer P., Vaughan CK, Panaretou B., Piper PW, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50cdc37. Cell 2004 ; 116: 87-98.
22. Riggs DL, Cox MB, Cheung-Flynn J., Prapapanich V., Carrigan PE, Smith DF: Functional specificity of cochaperone interactions with Hsp90 client proteins. Crit Rev Biochem Mol Biol 2004 ; 39: 279-295.